Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. - Wikidata - awgldk - TriplyDB

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

http://www.wikidata.org/entity/Q30372195

about

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target Considerations for the rapid deployment of vaccines against H7N9 influenza.Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets Inactivated influenza vaccines: recent progress and implications for the elderly.Pandemic influenza vaccines - the challenges.Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.Use of bacteriophage particles displaying influenza virus hemagglutinin for the detection of hemagglutination-inhibition antibodies.Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals.Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in health Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.Carbohydrate-based immune adjuvants.Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.Baculovirus vector as a delivery vehicle for influenza vaccines.Advances and challenges in the development and production of effective plant-based influenza vaccines.An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.Effect of receptor binding specificity on the immunogenicity and protective efficacy of influenza virus A H1 vaccines.H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines.XIth International Symposium on Respiratory Viral Infections.New Kids on the Block: RNA-Based Influenza Virus Vaccines.Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis

P2860

Q21091074-783E7733-7FDC-4B72-8B72-ED2B5E28B276 Q27336156-9EBB8E03-A12F-46F9-89C7-1AB9CAE596AB Q30204578-D3414DF9-63CC-4F52-AA76-DF45AD25E109 Q30227194-F5B9B984-7909-45BF-9DBE-F6898122D2BC Q30364635-C2D74F65-E522-4D92-B9A6-C2CCA408C2CF Q30375982-0D362731-793F-4431-96CF-517F0B557D6A Q30383451-B0D2DC78-FBE3-42FF-B863-D462156E853E Q30389582-8F35A596-4ED6-4FB6-9DDE-E8EEB973B067 Q30389924-2D5A7ED0-5AAD-403B-A352-84E950F87398 Q30390832-CA758952-8986-483B-B10D-E510EC265DCB Q30398516-58BF9E33-901E-467F-85FA-E96207787FFC Q30399057-4C0E7FC7-B619-405B-AFDA-6510D5D63194 Q30408091-70393430-C291-4DEF-B2C4-8EC5700F03AF Q30424758-1E50940D-1C26-4565-8308-1848C1660B01 Q33396140-AB5309FA-7E41-45FF-A678-8BE654953A7E Q33683079-073D35A3-5F50-4ABE-B449-1DB1F9ED6C60 Q33809686-500650EE-587F-464F-B876-EE538DC70093 Q33883224-85DDE7EF-1E8F-40EC-8D2E-E0ECEFA4A75F Q34497705-5185B18A-B219-4E89-857A-AE402D0438A6 Q34498228-92F7F945-9585-42E2-BAA3-92608A169A2A Q35054845-EA451111-BCA5-4578-94D6-F319616E0CE6 Q35866636-B23515C0-CA99-46CC-9975-8364151F9380 Q35887557-702C4C7C-C363-4E5A-B36C-C978C12BE50E Q36410040-AD6EBB2B-FBF3-4370-8E5C-AFC5F0DF6BC4 Q37316012-7F1D1DE4-0D6E-4549-903F-C375EC09112F Q37434539-3B9FDF22-6688-4FB0-910F-0563908D895D Q38285425-F562F54C-930C-478A-9094-9F02AD54B688 Q40782869-E4BF7CF0-B5AE-4EA9-9C58-D7D45BB22298 Q42202779-ED658E06-E581-4F22-9B16-1D1B367771B3 Q47149344-52395B6B-DDF2-47A4-9172-161393C75D0E Q49745741-D7A00106-1AE4-4F48-9FFC-0344C3A4B578 Q52609655-D9913A10-2517-48A3-8561-447A6E226119 Q57094173-00FF7357-7463-4F22-A09E-0225D8C50582

P2860

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

http://www.wikidata.org/entity/Q30372195

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Safety and immunogenicity of a ...... -II randomized clinical trial.

@ast

Safety and immunogenicity of a ...... -II randomized clinical trial.

@en

type

label

Safety and immunogenicity of a ...... -II randomized clinical trial.

@ast

Safety and immunogenicity of a ...... -II randomized clinical trial.

@en

prefLabel

Safety and immunogenicity of a ...... -II randomized clinical trial.

@ast

Safety and immunogenicity of a ...... -II randomized clinical trial.

@en

P1433

Q30372195-5827D3D4-6D90-4D79-9819-C1F4E4BEBAD9

P1476

Q30372195-55A46271-6F24-4391-BC01-0E51F3328CE2

P2093

Q30372195-2B300FBE-EC0A-4F07-B178-E848655D7BFB

Q30372195-5F077C6B-6377-4166-9542-F5BED1720760

Q30372195-764770FD-D2E0-47C2-9184-B3E1E2DBBAF9

Q30372195-8C43B6EA-8FCD-4B2C-8E13-89B0F5593E80

Q30372195-B90B66F1-BBF5-4D09-B287-EDD7B3FF6B85

Q30372195-C0CA5DD8-4E11-4D0A-8CF3-1A78CA33CF3D

Q30372195-D6DB2AE8-6574-4302-B76C-A76A781815FF

P2860

Q30372195-10A89475-2A9A-4D7B-A097-56251A55E672

Q30372195-138B0228-921D-4B4D-8B62-7791729F2756

Q30372195-1744C6DC-A2F9-426F-A95E-0DB04B84052F

Q30372195-17BEE446-A8C2-45DF-85D7-74208271131E

Q30372195-2A1D3B87-02EB-4629-8051-D09197FBFCE9

Q30372195-38160F93-CA75-4D65-B9B6-F1C1FC89A967

Q30372195-3D7E9BAC-31F9-49C4-86A2-82B1CB16EEC9

Q30372195-4CAEA986-730A-4D4B-A517-320760AB7765

Q30372195-4D8FBF84-DE7A-4251-AD04-7046D7F10FCD

Q30372195-6C2CB1EA-6251-4E55-9C43-4CE742FFA3F1

P304

Q30372195-F654984D-4576-4A0C-BCF5-896524F9CB5E

P31

Q30372195-0C9A659E-6ABD-4591-A6F2-9571386C7239

P356

Q30372195-3E81B675-5B6C-43EF-B38C-B0326F6BE3D5

P407

Q30372195-E5A5E81A-9065-49F2-8143-33373C72AA1E

P433

Q30372195-30EA2609-73B3-490E-B437-701748CA711F

P478

Q30372195-3BD19645-C163-45A3-BA9A-09D40105A751

P50

Q30372195-0F99375C-B3CF-4BE1-9394-09F87C089D5D

P577

Q30372195-69FF10A2-0538-4040-BE92-B7183D9CBD51

P5875

Q30372195-BCA6ADD0-0210-4249-9026-AA3FB21E70F2

P698

Q30372195-5AB39A13-71DC-4F06-8F40-86DD300BD514

P921

Q30372195-20e26ac8-d616-4ac8-b82f-fee67db9b3bd

Q30372195-D022CD21-202D-452C-96FC-50088C405CA0

Q30372195-E677874F-8718-4CAF-9E2F-B77BA844B2AA

P932

Q30372195-02BC225F-125E-4A0A-A84D-B645BE2C874E

P356

P1433

The Journal of Infectious Diseases

P1476

Safety and immunogenicity of a ...... -II randomized clinical trial.

@en

P2093

Diana L Noah

http://www.w3.org/2001/XMLSchema#string

Emmanuel B Walter

http://www.w3.org/2001/XMLSchema#string

Fenhua He

http://www.w3.org/2001/XMLSchema#string

Heather Hill

http://www.w3.org/2001/XMLSchema#string

James D Campbell

http://www.w3.org/2001/XMLSchema#string

John J Treanor

http://www.w3.org/2001/XMLSchema#string

Shital M Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Inactivated whole virus influenza A (H5N1) vaccine

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.

High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.

P304

1309-1316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/592172

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

198

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23274225

http://www.w3.org/2001/XMLSchema#string

P698

18808338

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

P932

3044935

http://www.w3.org/2001/XMLSchema#string